Champalimaud Foundation in the news

Botond Roska and José-Alain Sahel were awarded the 2026 António Champalimaud Vision Award for their research in retinal function and vision restoration, including successful optogenetic therapy in blind patients.

The Champalimaud Foundation is leading the development of a 15.8 million euro European AI research project called ResPECT, which aims to create an AI assistant to transform patient words into clinical information.

Champalimaud Foundation is leading a new 15.8 million euro European project, ResPECT, to develop an AI assistant that converts patient narratives into clinical data for oncology and mental health care.

Champalimaud Foundation is spearheading the development of ResPECT, a –15.8 million European AI project to convert patient experiences into clinical data.

The Champalimaud Foundation awarded researchers Botond Roska and José-Alain Sahel for their pioneering optogenetic therapies that restore partial vision to blind individuals.

José-Alain Sahel and Botond Roska won the António Champalimaud Vision Award for their innovative optogenetic therapies aimed at restoring vision loss from retinal diseases.

Researchers Botond Roska and José-Alain Sahel received the 2026 António Champalimaud Prize for their optogenetics-based therapies that restore sight in blind individuals.

Vítor Cunha, former CEO of Kreab Portugal, will become the executive secretary-general of the Champalimaud Foundation starting September 1st.

Helena Cruz, from Champalimaud Foundation, was selected for the Health Parliament Portugal, a program aimed at shaping the future of healthcare in Portugal.

Eduard-Alexandru Bonci of Champalimaud Foundation shared a new EUSOMA paper addressing unequal access to high-quality cancer care across Europe.

Champalimaud Foundation's Maria João Cardoso hosted a Medica AI community gathering for AI and cancer research, emphasizing collaboration and human connections.

Maria João Cardoso announced the BCRP Awards 2026, celebrating three innovative breast cancer research teams and thanking sponsors Simoldes and Delta Cafés.

John Krakauer, an SFI External Professor, was named director of the Centre for Restorative Neurotechnology at the Champalimaud Foundation, a center he helped create, focusing on turning neuroscience research into treatments.

John Krakauer was named director of the Centre for Restorative Neurotechnology at the Champalimaud Foundation, focusing on neuro-rehabilitation and stroke recovery.

Researchers at the Champalimaud Foundation discovered a network of brain circuits that could revolutionize the treatment of obsessive-compulsive disorder, making therapies more targeted and effective.

Champalimaud Foundation researchers mapped neural circuits linked to OCD, offering a new approach for more individualized and effective treatments.

Champalimaud Foundation researchers identified a brain circuit, published in Biological Psychiatry, that could lead to more personalized and effective treatments for obsessive-compulsive disorder by guiding neuromodulation therapies.

A clinical research fellow at the Champalimaud Foundation is advocating for the responsible use of AI in breast cancer treatment through specialized research projects and educational outreach.

Champalimaud Foundation has installed a world-record 18 Tesla MRI system from Bruker to enhance its preclinical research in oncology and neuroscience.

Champalimaud Foundation has commissioned a world-first 18 Tesla ultra-high field MRI scanner to advance its preclinical research in oncology and neuroscience.